TapewireFind a company

person · Reporting owner

Huizenga Theodore Alan

Disclosed activity across 1 company

Tapewire entity
51309
SEC CIK
0001603347

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337SVP, Chief Accounting OfficerSeptember 15, 2026September 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Ultragenyx Pharmaceutical Inc.

Report date September 15, 2026 · Filed September 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect67,863 Reported balance After 2026-09-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-15 · Sale · Disposed 1,283 · Balance 67,863

F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 15, 2026 Filed Sep 15, 2026 22:57 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 1,283 $13.57 $17,410.31
Disclosure

SEC source: 0001193125-26-392233 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,863

F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
September 03, 2026 Filed Sep 8, 2026 16:29 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 161 $13.99 $2,252.39
Disclosure

SEC source: 0001193125-26-384878 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,146

F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F2 · balance_after: Includes 396 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026.

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
April 22, 2026 Filed Apr 24, 2026 20:39 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 7,348 $0.00 Strike: $24.61 $0.00
Disclosure

SEC source: 0001193125-26-177470 · ownership.xml · derivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,348

Underlying: Common Stock · 7,348 shares

Expires 2036-04-22

F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Read SEC document
April 22, 2026 Filed Apr 24, 2026 20:39 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 20,241 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-177470 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,911

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 23:51 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 1,632 $22.80 $37,209.60
Disclosure

SEC source: 0001193125-26-089109 · ownership.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,670

F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 23:51 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Tax withholdingCommon Stock 148 $23.39 $3,461.72
Disclosure

SEC source: 0001193125-26-089109 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,302

F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.

Read SEC document
December 29, 2025 Filed Dec 30, 2025 18:49 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 85 $34.38 $2,922.30
Disclosure

SEC source: 0001193125-25-336619 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,450

F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F2 · balance_after: Includes 293 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on October 31, 2025.

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
September 18, 2025 Filed Sep 19, 2025 22:23 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 64 $29.17 $1,866.88
Disclosure

SEC source: 0001193125-25-209387 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,242

F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
September 05, 2025 Filed Sep 8, 2025 18:01 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 84 $31.39 $2,636.76
Disclosure

SEC source: 0000950170-25-113446 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,306

F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F2 · balance_after: Includes 266 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on April 30, 2025.

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 01:00 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Tax withholdingCommon Stock 141 $42.92 $6,051.72
Disclosure

SEC source: 0000950170-25-032764 · ownership.xml · nonDerivative · entry 3

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,124

F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.

F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 01:00 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 967 $42.10 $40,710.70
Disclosure

SEC source: 0000950170-25-032764 · ownership.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,265

F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
March 01, 2025 Filed Mar 5, 2025 01:00 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 5,632 $0.00 Strike: $42.92 $0.00
Disclosure

SEC source: 0000950170-25-032764 · ownership.xml · derivative · entry 4

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,632

Underlying: Common Stock · 5,632 shares

Expires 2035-03-01

F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Read SEC document
March 01, 2025 Filed Mar 5, 2025 01:00 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 9,392 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-032764 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,232

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

Read SEC document
December 10, 2024 Filed Dec 11, 2024 23:47 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GiftCommon Stock 648 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-135525 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,840

F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

F2 · balance_after: Includes 237 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on October 31, 2024.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 17:03 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 700 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-107677 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,251

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 15:50 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 91 $56.19 $5,113.29
Disclosure

SEC source: 0000950170-24-103807 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,551

F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F2 · balance_after: Includes 276 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on April 30, 2024

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
April 16, 2024 Filed Apr 18, 2024 22:06 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Tax withholdingCommon Stock 14 $42.31 $592.34
Disclosure

SEC source: 0000950170-24-045670 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,366

F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.

F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:13 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 2,351 $0.00 Strike: $67.37 $0.00
Disclosure

SEC source: 0000950170-24-026641 · ownership.xml · derivative · entry 5

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,351

Underlying: Common Stock · 2,351 shares

Expires 2027-03-01

F6 · derivative.exercise_date: On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On March 1, 2024, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 1,568 shares on that date.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:13 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 8,200 $0.00 Strike: $53.69 $0.00
Disclosure

SEC source: 0000950170-24-026641 · ownership.xml · derivative · entry 4

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 8,200 shares

Expires 2034-03-01

F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:13 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 341 $53.76 $18,332.16
Disclosure

SEC source: 0000950170-24-026641 · ownership.xml · nonDerivative · entry 3

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,380

F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:13 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Tax withholdingCommon Stock 121 $53.69 $6,496.49
Disclosure

SEC source: 0000950170-24-026641 · ownership.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,721

F2 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:13 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 13,950 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026641 · ownership.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,842

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

Read SEC document
January 02, 2024 Filed Jan 2, 2024 21:06 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Exercise / conversionStock Option (Right to Buy) · Derivative 3,000 $0.00 Strike: $21.00 $0.00
Disclosure

SEC source: 0001209191-24-000070 · doc4.xml · derivative · entry 3

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires 2024-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.

Read SEC document
January 02, 2024 Filed Jan 2, 2024 21:06 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Exercise / conversionCommon Stock 3,000 $21.00 $63,000.00
Disclosure

SEC source: 0001209191-24-000070 · doc4.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,892

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: Includes 278 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 20, 2023 Filed Jan 2, 2024 21:06 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 1,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-000070 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,614

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.

Read SEC document
September 27, 2023 Filed Sep 29, 2023 18:16 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 2,351 $0.00 Strike: $67.37 $0.00
Disclosure

SEC source: 0001209191-23-050841 · doc4.xml · derivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,351

Underlying: Common Stock · 2,351 shares

Expires 2027-03-01

F2 · derivative.exercise_date: On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On September 27, 2023, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 784 shares on that date.

Read SEC document
September 07, 2023 Filed Sep 11, 2023 17:52 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Exercise / conversionStock Option (Right to Buy) · Derivative 2,000 $0.00 Strike: $21.00 $0.00
Disclosure

SEC source: 0001209191-23-048905 · doc4.xml · derivative · entry 4

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 2,000 shares

Expires 2024-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.

Read SEC document
September 07, 2023 Filed Sep 11, 2023 17:52 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 163 $38.34 $6,249.42
Disclosure

SEC source: 0001209191-23-048905 · doc4.xml · nonDerivative · entry 3

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,614

F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
September 07, 2023 Filed Sep 11, 2023 17:52 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 2,000 $41.00 $82,000.00
Disclosure

SEC source: 0001209191-23-048905 · doc4.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,777

Read SEC document
September 07, 2023 Filed Sep 11, 2023 17:52 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Exercise / conversionCommon Stock 2,000 $21.00 $42,000.00
Disclosure

SEC source: 0001209191-23-048905 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,777

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 21:50 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 87 $38.23 $3,326.01
Disclosure

SEC source: 0001209191-23-048489 · doc4.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,777

F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").

F3 · balance_after: The total amount of securities beneficially owned by the Reporting Person reflected in Table 1, Column 5 of this Form 4 reflects the correction of a typographical error in a previously filed Form 4 filed on April 18, 2023 ("April 2023 Form 4"). The corrected total amount of securities beneficially owned by the Reporting Person in Table 1, Column 5 of the April 2023 Form 4 is 21,520. The corrected total amount of securities beneficially owned by the Reported Person in Table 1, Column 5 of the Form 4 filed on behalf of the Reporting Person on May 10, 2023 is 24,747.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 21:50 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 883 $37.04 $32,706.32
Disclosure

SEC source: 0001209191-23-048489 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,864

F1 · shares: The sale reported on this row of the Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.

Read SEC document
May 09, 2023 Filed May 11, 2023 00:09 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Exercise / conversionStock Option (Right to Buy) · Derivative 3,000 $0.00 Strike: $21.00 $0.00
Disclosure

SEC source: 0001209191-23-028585 · doc4.xml · derivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 3,000 shares

Expires 2024-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.

Read SEC document
May 09, 2023 Filed May 11, 2023 00:09 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Exercise / conversionCommon Stock 3,000 $21.00 $63,000.00
Disclosure

SEC source: 0001209191-23-028585 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,747

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 227 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023.

F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
April 16, 2023 Filed Apr 18, 2023 20:57 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Disposition to issuerCommon Stock 181 $38.20 $6,914.20
Disclosure

SEC source: 0001209191-23-024685 · doc4.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,520

F2 · shares: Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
April 16, 2023 Filed Apr 18, 2023 20:57 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Tax withholdingCommon Stock 14 $38.20 $534.80
Disclosure

SEC source: 0001209191-23-024685 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,701

F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").

Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:54 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 10,120 $0.00 Strike: $45.65 $0.00
Disclosure

SEC source: 0001209191-23-016045 · doc4.xml · derivative · entry 4

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,120

Underlying: Common Stock · 10,120 shares

Expires 2033-03-01

F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:54 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 Disposition to issuerCommon Stock 1,333 $45.65 $60,851.45
Disclosure

SEC source: 0001209191-23-016045 · doc4.xml · nonDerivative · entry 3

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,715

F3 · shares: Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:54 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 100 $45.65 $4,565.00
Disclosure

SEC source: 0001209191-23-016045 · doc4.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,048

F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:54 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 7,590 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016045 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,148

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 19:28 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 639 $43.40 $27,732.60
Disclosure

SEC source: 0001209191-23-014502 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,558

F1 · kind: The transaction reported on this Form 4 was effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
December 21, 2022 Filed Dec 22, 2022 18:24 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 2,031 $43.96 $89,282.76
Disclosure

SEC source: 0001209191-22-062400 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,197

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes 134 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2022

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
September 01, 2022 Filed Sep 8, 2022 22:36 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 1,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-049222 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,094

F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.

F2 · balance_after: Includes 180 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2022.

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
April 16, 2022 Filed Apr 19, 2022 16:56 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 132 $84.55 $11,160.60
Disclosure

SEC source: 0001209191-22-024699 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,914

F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").

F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:09 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantStock Option (Right to Buy) · Derivative 7,400 $0.00 Strike: $67.37 $0.00
Disclosure

SEC source: 0001209191-22-015819 · doc4.xml · derivative · entry 3

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,400

Underlying: Common Stock · 7,400 shares

Expires 2032-03-01

F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:09 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GrantCommon Stock 3,710 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-015819 · doc4.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,046

F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.

F3 · balance_after: Includes 107 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 29, 2021.

F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:09 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 843 $66.62 $56,160.66
Disclosure

SEC source: 0001209191-22-015819 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,229

F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").

Read SEC document
October 14, 2021 Filed Oct 18, 2021 22:53 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 140 $81.14 $11,359.60
Disclosure

SEC source: 0001209191-21-060756 · doc4.xml · nonDerivative · entry 2

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,072

F1 · kind: Represents shares sold by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").

F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document
September 13, 2021 Filed Oct 18, 2021 22:53 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 GiftCommon Stock 819 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-060756 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,212

Read SEC document
May 06, 2021 Filed May 10, 2021 22:12 UTC Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 SaleCommon Stock 142 $113.67 $16,141.14
Disclosure

SEC source: 0001209191-21-031386 · doc4.xml · nonDerivative · entry 1

Huizenga Theodore Alan · CIK 0001603347 · SVP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,031

F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F2 · balance_after: Includes 129 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2021.

F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.